Patents by Inventor Michael Liam COOKE
Michael Liam COOKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939321Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: April 7, 2021Date of Patent: March 26, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
-
Publication number: 20240018111Abstract: The invention relates to compounds of formula (I): wherein A, RA1, RA2, RB, RC and RD are as defined herein, and associated aspects.Type: ApplicationFiled: August 5, 2021Publication date: January 18, 2024Applicant: Sitryx Therapeutics LimitedInventors: Saleh AHMED, Michael Liam COOKE, Matthew Colin Thor FYFE
-
Publication number: 20240010606Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.Type: ApplicationFiled: August 20, 2021Publication date: January 11, 2024Applicant: Sitryx Therapeutics LimitedInventors: Michael Liam COOKE, Matthew Colin Thor FYFE, Barry John TEOBALD
-
Publication number: 20230219907Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.Type: ApplicationFiled: December 23, 2020Publication date: July 13, 2023Applicant: Sitryx Therapeutics LimitedInventors: Michael Liam COOKE, David COUSIN, Matthew Colin Thor FYFE, Thomas Michael WAUGH, Saleh AHMED, Alessio DE SIMONE, Barry John TEOBALD
-
Publication number: 20230019032Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: ApplicationFiled: April 7, 2021Publication date: January 19, 2023Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio BERDINI, Ildiko Maria BUCK, James Edward Harvey DAY, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Steven HOWARD, Christopher William MURRAY, David NORTON, Marc O'REILLY, Alison Jo-Anne WOOLFORD, Michael Liam COOKE, David COUSIN, Stuart Thomas ONIONS, Jonathan Martin SHANNON, John Paul WATTS
-
Publication number: 20220265595Abstract: The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.Type: ApplicationFiled: April 30, 2020Publication date: August 25, 2022Inventors: Michael Liam COOKE, David COUSIN, Matthew Colin Thor FYFE, Barry John TEOBALD, Stephen Malcolm THOM, Thomas Michael WAUGH
-
Patent number: 11001575Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: August 15, 2019Date of Patent: May 11, 2021Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
-
Patent number: 10457669Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: October 20, 2016Date of Patent: October 29, 2019Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
-
Publication number: 20190047990Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: ApplicationFiled: October 20, 2016Publication date: February 14, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio BERDINI, Ildiko Maria BUCK, James Edward Harvey DAY, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Steven HOWARD, Christopher William MURRAY, David NORTON, Marc O'REILLY, Alison Jo-Anne WOOLFORD, Michael Liam COOKE, David COUSIN, Stuart Thomas ONIONS, Jonathan Martin SHANNON, John Paul WATTS